Black Diamond Therapeutics Inc
BDTX
Company Profile
Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Contact
One Main Street
14th Floor
CambridgeMA02142
USAT: +1 617 252-0848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
54
Stocks News & Analysis
stocks
ASX listed gold miner under pressure due to lower production
Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,838.90 | 5.40 | 0.06% |
| CAC 40 | 7,974.49 | 38.52 | 0.49% |
| DAX 40 | 23,730.92 | 166.91 | 0.71% |
| Dow JONES (US) | 46,993.26 | 46.85 | 0.10% |
| FTSE 100 | 10,403.60 | 85.91 | 0.83% |
| HKSE | 25,853.26 | 15.28 | -0.06% |
| NASDAQ | 22,479.53 | 105.35 | 0.47% |
| Nikkei 225 | 54,898.44 | 1,198.05 | 2.23% |
| NZX 50 Index | 13,289.29 | 107.06 | 0.81% |
| S&P 500 | 6,716.09 | 16.71 | 0.25% |
| S&P/ASX 200 | 8,632.40 | 6.20 | 0.07% |
| SSE Composite Index | 4,037.11 | 12.80 | -0.32% |